Loading decisions…
Loading decisions…
1,253 vetted Board decisions in 2025.
The Board granted service connection for prostate cancer, diabetes mellitus, atherosclerotic cardiovascular disease with stable angina, and lung cancer based on the presumption of herbicide exposure during service in Korea.
The Veteran withdrew all appeals, including those for service connection and higher ratings for various conditions.
The Board denied service connection for prostate cancer, hemophilia, and diabetes mellitus (type 1 or type 2) as the evidence did not support a finding of an in-service incurrence or relationship to service.
The Board granted service connection for the cause of the Veteran's death, finding that his prostate cancer was related to in-service asbestos exposure.
The Veteran withdrew his appeal for service connection for prostate cancer, and the Board has no jurisdiction to review this claim.
The Board granted service connection for prostate cancer, Parkinson's disease, type 2 diabetes mellitus, and erectile dysfunction (ED) as secondary to service-connected disabilities.
The Board granted service connection for a heart disability, to include coronary artery disease and valvular heart disease, and prostate cancer residuals under the PACT Act.
The Board remands the claim for service connection for prostate cancer to correct a pre-decisional duty to assist error, specifically to obtain an adequate medical opinion regarding the etiology of the Veteran's condition.
The Board granted service connection for kidney cancer as secondary to the service-connected hypertension and granted a total rating based on individual employability due to service-connected disabilities from March 19, 2024. Other claims were denied.
The Board granted the restoration of the 100 percent rating for prostate cancer, which was previously reduced to 20 percent effective October 1, 2024.
The Veteran withdrew all pending claims, and the Board has no jurisdiction to review these issues.
The Board restored the 100 percent rating for prostate cancer effective April 1, 2024, as the procedural requirements were not met during the reduction process. The claim for an increased rating is rendered moot.
The Board denied the veteran's claims for an increased rating for residuals of prostate cancer and individual unemployability.
The Board remands the claim for service connection of residuals of prostate cancer to ensure that the case is forwarded to the Under Secretary for Benefits for consideration under 38 C.F.R. § 3.311.
The Veteran's eligibility for specially adapted housing is granted due to his service-connected disabilities, specifically prostate cancer and metastatic bone cancer, which have rendered him unable to walk.
The Board remands the claims for service connection for prostate cancer and ulcerative colitis, colon polyps, irritable bowel syndrome, and diverticular disease due to inadequate medical opinions.
The Board denied service connection for a thyroid disability and prostate cancer, as the evidence did not support a medical nexus to the Veteran's military service.
The Board dismissed the Veteran's motion for revision based on clear and unmistakable error (CUE) in an April 2022 rating decision, as it was not properly raised with the AOJ first.
The Veteran's prostate cancer residuals are granted a 60 percent rating from July 7, 2023.
The Board remands the claims for service connection for prostate cancer and a back condition due to pre-decisional duty to assist errors.
← Back to Prostate cancer overview
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.